Antibody-drug conjugates (ADCs) are reshaping targeted cancer therapy, but traditional conjugation methods often fall short due to unstable linkers and inconsistent drug-to-antibody ratios (DAR). Abzena’s ThioBridge™ conjugation technology overcomes these limitations by providing a controlled, stable, and uniform attachment of payloads to antibodies — improving the stability, potency and pharmacokinetic properties of ADCs.
Studies have shown that ThioBridge™ ADCs maintain serum stability, demonstrate superior potency in tumour models, and deliver consistent efficacy compared to maleimide-based conjugates. The process is simple, efficient, and adaptable to various linker architectures, ensuring robust and scalable ADC development.
Download the full white paper here to explore how ThioBridge™ enables the next generation of stable, effective antibody-drug conjugates.
